Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), retaining the price ...

On Wednesday, Seres Therapeutics Inc (MCRB) stock saw a decline, ending the day at $0.59 which represents a decrease of $-0.07 or -10.61% from the prior close of $0.66. The stock opened at $0.65 and ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Thank you for standing by. My name is Bella, and I will be your ...

Seres Therapeutics Inc. ( (MCRB) ) has released its Q3 earnings. Here is a breakdown of the information Seres Therapeutics Inc. presented to ...

Seres Therapeutics Inc (MCRB) reports promising clinical results and strategic financial maneuvers, despite facing increased ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Seres Therapeutics Inc. (MCRB) on Wednesday reported third-quarter earnings of $88.8 million. The Cambridge, Massachusetts-based company said it had ...

Detailed price information for Seres Therapeutics Inc (MCRB-Q) from The Globe and Mail including charting and trades.

Seres Therapeutics (NASDAQ:MCRB) is scheduled to announce Q3 earnings results on Wednesday, November 13th, before market open ...

Analysts are estimating that Seres Therapeutics will report an earnings per share (EPS) of $-0.24. Seres Therapeutics bulls ...